Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Employment (1)

Princess Margaret Cancer Center: Toronto, ON, CA

Employment
Source: Self-asserted source
srikala sridhar

Works (10)

Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey

Cancers
2025-02-03 | Journal article
DOI: 10.3390/cancers17030509
Contributors: Richard O’Dwyer; Sophia Junker; Robert Szulkin; Scarlette Kienzle; Mairead Kearney; Srikala S. Sridhar
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Data from Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

2025-01-06 | Preprint
DOI: 10.1158/1078-0432.c.7611414
Contributors: Eric Winquist; Sebastien J. Hotte; Kim Chi; Srikala Sridhar; Susan Ellard; Michael Ong; Nayyer Iqbal; Muhammad Salim; Urban Emmenegger; Joel R. Gingerich et al.
Source: check_circle
Crossref

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research
2025-01-06 | Journal article
DOI: 10.1158/1078-0432.CCR-24-1612
Contributors: Eric Winquist; Sebastien J. Hotte; Kim Chi; Srikala Sridhar; Susan Ellard; Michael Ong; Nayyer Iqbal; Muhammad Salim; Urban Emmenegger; Joel R. Gingerich et al.
Source: check_circle
Crossref

Supplementary Table 1 from Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

2025-01-06 | Preprint
DOI: 10.1158/1078-0432.28141743
Contributors: Eric Winquist; Sebastien J. Hotte; Kim Chi; Srikala Sridhar; Susan Ellard; Michael Ong; Nayyer Iqbal; Muhammad Salim; Urban Emmenegger; Joel R. Gingerich et al.
Source: check_circle
Crossref

Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift

Nature Reviews Clinical Oncology
2024-04 | Journal article
DOI: 10.1038/s41571-024-00861-7
Contributors: Nimira Alimohamed; Srikala S. Sridhar
Source: check_circle
Crossref

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

Journal of Clinical Oncology
2023-07-01 | Journal article
DOI: 10.1200/JCO.22.01792
Contributors: Thomas Powles; Se Hoon Park; Claudia Caserta; Begoña P. Valderrama; Howard Gurney; Anders Ullén; Yohann Loriot; Srikala S. Sridhar; Cora N. Sternberg; Joaquim Bellmunt et al.
Source: check_circle
Crossref

Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study

The Breast
2021-08 | Journal article
DOI: 10.1016/j.breast.2021.04.005
Contributors: Cynthia Maxwell; Sepand Alavifard; Ellen Warner; Maru Barrera; Christine Brezden-Masley; Nicolas Colapinto; Shima Kassirian; Yolanda Madarnas; Sridhar Srikala; Richard Tozer et al.
Source: check_circle
Crossref

Defining cisplatin eligibility in patients with muscle-invasive bladder cancer

Nature Reviews Urology
2021-02 | Journal article
DOI: 10.1038/s41585-020-00404-6
Contributors: Di Maria Jiang; Shilpa Gupta; Abhijat Kitchlu; Alejandro Meraz-Munoz; Scott A. North; Nimira S. Alimohamed; Normand Blais; Srikala S. Sridhar
Source: check_circle
Crossref

Key Perspectives on Managing Older Patients with Prostate Cancer: What We Know About the Fit and What We Need to Know About the Frail

European Urology Oncology
2020-08 | Journal article
DOI: 10.1016/j.euo.2020.05.006
Contributors: Srikala S. Sridhar; Shabbir M.H. Alibhai
Source: check_circle
Crossref

Enfortumab Vedotin in urothelial cancer

Therapeutic Advances in Urology
2020-01 | Journal article
DOI: 10.1177/1756287220980192
Contributors: Marie Alt; Carlos Stecca; Swanee Tobin; Di Maria Jiang; Srikala S. Sridhar
Source: check_circle
Crossref

Peer review (4 reviews for 4 publications/grants)

Review activity for European journal of cancer. (1)
Review activity for JNCI cancer spectrum. (1)
Review activity for Nature reviews. (1)
Review activity for The lancet oncology. (1)
How many people are using ORCID?